On our screens:Quality at a reasonable price
The financials
Integer Holdings Corporation by the numbers
Integer Holdings Corporation (ITGR) reported revenue of $440M in Q1 2026 (quarter ended Apr 3, 2026), up 0.5% from the same quarter a year earlier. That came with a gross margin of 25% and net income of $17M (3.8% of revenue). For the full year FY2025, revenue was $1.85B (+8.0% year on year) and net income $103M. Its largest product in Jun 2026 was Cardio And Vascular at $280M, 60% of the disclosed total, well ahead of Cardiac Rhythm Management Neuromodulation at 37%.
| Income statement | Q1 2026 | Q1 2025 | Change |
|---|---|---|---|
| Revenue | $440M | $437M | +0.5% |
| Gross profit | $110M | $120M | −8.9% |
| Operating income | $32M | $50M | −36% |
| Net income | $17M | −$22M | to a profit |
| Diluted EPS | $0.48 | −$0.66 | to a profit |
| Product | Revenue | Share |
|---|---|---|
| Cardio And Vascular | $280M | 60% |
| Cardiac Rhythm Management Neuromodulation | $174M | 37% |
| Other Markets | $10M | 2.2% |
Business Segments
Revenue split by product segment, from SEC XBRL filings.
Latest period: Jun 2026Total $464.1M (+5.6%)
Cardiac Rhythm Management Neuromodulation grew +1.00% year on yearOther Markets -43% year on year
Segment Latestquarter on quarteryear on year
- Cardio And Vascular$280.3M$280.3MQoQ +7.1%year on year -2.3%+7.1%-2.3%
- Cardiac Rhythm Management Neuromodulation$173.7M$173.7MQoQ +3.2%year on year +1.00%+3.2%+1.00%
- Other Markets$10.1M$10.1MQoQ +5.3%year on year -43%+5.3%-43%